The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
Open accessAbstract
BACKGROUND: Chronic pruritus is a global clinical problem with a high impact on the quality of life and lack of specific therapies. It is an excruciating and frequent symptom of e.g. uncurable renal, liver and skin diseases which often does not respond to conventional treatment with e.g. antihistamines. Therefore antipruritic therapies which target physiological mechanisms of pruritus need to be developed. Substance P (SP) is a major mediator of pruritus. As it binds to the neurokinin receptor 1 (NKR1), we evaluated if the application of a NKR1 antagonist would significantly decrease chronic pruritus. METHODS AND FINDINGS: Twenty hitherto untreatable patients with chronic pruritus (12 female, 8 male; mean age, 66.7 years) were treated with the NKR1 antagonist aprepitant 80 mg for one week. 16 of 20 patients (80%) experienced a considerable reduction of itch intensity, as assessed by the visual analog scale (VAS, range 0 to 10). Considering all patients, the mean value of pruritus intensity was significantly reduced from 8.4 VAS points (SD +/-1.7) before treatment to 4.9 VAS points (SD +/-3.2) (p<0.001, CI 1.913-5.187). Patients with dermatological diseases (e.g. atopic diathesis, prurigo nodularis) had the best profit from the treatment. Side-effects were mild (nausea, vertigo, and drowsiness) and only occurred in three patients. CONCLUSIONS: The high response rate in patients with therapy refractory pruritus suggests that the NKR1 antagonist aprepitant may indeed exhibit antipruritic effects and may present a novel, effective treatment strategy based on pathophysiology of chronic pruritus. The results are promising enough to warrant confirming the efficacy of NKR1 antagonists in a randomized, controlled clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ikoma, A., Steinhoff, M., Ständer, S., Yosipovitch, G., & Schmelz, M. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1950 · Cited by 949
Self-citationHesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., Chawla, S. P., Carides, A. D., Ianus, J., Elmer, M. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.095 · Cited by 779
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
Ständer, S., Weisshaar, E., Mettang, T., Szepietowski, J., Carstens, E., Ikoma, A., Bergasa, N., Gieler, U., Misery, L., Wallengren, J., et al. (2007) · Acta Dermato-Venereologica · doi:10.2340/00015555-0305 · Cited by 763
Self-citationNeuropeptides activate human mast cell degranulation and chemokine production
Kulka, M., Sheen, C. H., Tancowny, B. P., Grammer, L. C., & Schleimer, R. P. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02705.x · Cited by 445
Kumagai, H., Ebata, T., Takamori, K., Muramatsu, T., Nakamoto, H., & Suzuki, H. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp588 · Cited by 356
Tachykinins and Tachykinin Receptors: Structure and Activity Relationships
Almeida, T. A., Rojo, J., Nieto, P. M., Pinto, F. M., Hernandez, M., Martín, J. D., & Candenas, M. L. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364748 · Cited by 310
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286
Epidemiology of Itch: Adding to the Burden of Skin Morbidity
Weisshaar, E., & Dalgard, F. (2009) · Acta Dermato Venereologica · doi:10.2340/00015555-0662 · Cited by 237
Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema
Järvikallio, A., Harvima, I. T., & Naukkarinen, A. (2003) · Archives of Dermatological Research · doi:10.1007/s00403-002-0378-z · Cited by 234
Andoh, T., Nagasawa, T., Satoh, M., & Kuraishi, Y. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37703-1 · Cited by 233
Cited by
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628
European S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Self-citationMediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8488-5 · Cited by 353
Choi, J. E., & Di Nardo, A. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0675-z · Cited by 331
Nattkemper, L. A., Tey, H. L., Valdes-Rodriguez, R., Lee, H., Mollanazar, N. K., Albornoz, C., Sanders, K. M., & Yosipovitch, G. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.12.029 · Cited by 310
Metadata
- Authors
- Ständer, S., Siepmann, D., Herrgott, I., Sunderkötter, C., & Luger, T. A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-06-04
- Volume
- 5
- Issue
- 6
- Pages
- e10968
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2068736424
- Cited by
- 293
- References
- 32
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy. https://app.cochat.ai/papers/10.1371/journal.pone.0010968
- The paper
- Ständer, S., Siepmann, D., Herrgott, I., Sunderkötter, C., & Luger, T. A. (2010). Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy. PLoS ONE. https://doi.org/10.1371/journal.pone.0010968
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.